Abstract
Much effort has converged on finding an agent capable of activating the final common pathway of the coagulation cascade inducing hemostasis independently of factor VIII (F.VIII) or factor IX (RIX). Such an agent should be not only hemostatically active but also safe with respect to thromboembolic complications. Factor Vila (F.VIIa) becomes proteolytically active when complexed with tissue factor or other phopholipids minimizing the risk of inducing systemic activation of the coagulation system.
Keywords
- Prothrombin Time
- Tissue Factor
- Disseminate Intravascular Coagulation
- Tranexamic Acid
- Disseminate Intravascular Coagulation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
U. Hedner, W. Kisiel, Use of human factor Vila in treatment of two haemophilia A patients with high-titer inhibitors, J Clin Invest. 71: 1836 (1983).
. U. Hedner, S. Bjoern, S.S. Bernvil, L. Tengborn, L. Stigendahl, Clinical experience with human plasma-derived factor Vila in patients with hemophilia A and high-titer inhibitors, Haemostasis. 19: 335 (1989).
F.S, Hagen, CL. Gray, P. O’Hara, FJ. Grant, G.C. Saari, R.G. Woodbury, CE. Hart, M. Insley, W. Kisiel, K. Kurachi, E.W. Davie, Characterization of a cDNA coding for human factor VII, Proc Nat’l Acad Sci USA. 83: 2413 (1986).
. L. Thim, S. Bjoern, M. Christensen, E.M. Nicolaisen, T. Lund-Hansen, AH. Pedersen, U. Hedner, Amino acid sequence and posttranslational modifications of human factor Vila from plasma and transfected baby hamster kidney cells. Biochemistry. 27: 7785 (1988).
U. Hedner, T. Lund-Hansen, D. Winther, Comparison of the effect of factor VII prepared from human plasma and recombinant Vila in vitro and in rabbits, Thromb Haemost. 58: 270a (1987).
U. Hedner, J. Ljungberg, T. Lund-Hansen, Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model, Blood and Fibrinol. 1: 145 (1990).
K.M. Brinkhous, U. Hedner, J.B. Garrís, V. Diness, M.S. Read, Effect of recombinant factor Vila on the hemostatic defect in dogs with hemophilia, hemophilia B, and von Willebrand disease, Proc Natl Acad Sci USA. 86: 1382 (1989).
. S.I. Rapaport, Inhibition of factor Vila/tissue factor-induced blood coagulation: With particular emphasis upon a factor Xa-dependent inhibitory mechanism, Blood73: 359 (1989).
U. Hedner, S. Schulman, K.A. Alberts, M. Blomback, H. Johnsson, S. Glazer, K. Pingel, Successful use of rFVIIa in a patient with severe hemophilia A subjected to synovectomy. Lancet. ii: 193 (1988).
G.B. Macik, H. Hohneker, H. Roberts, A.M. Griffin, The use of recombinant activated factor VII for treatment of a retropharyngeal haemorrhage in a hemophilic patient with a high-titer inhibitor. Am J Hematology. 32: 232 (1989).
S.A. Grupp, S. Glazer, D.A. Williams, Recalcitrant epistaxis in a hemophiliac with inhibitors: Experience with recombinant factor Vila. Blood 74(Suppl 1 ): 3901 (abstract no. 1489) (1989).
M.L. Schmidt, H.E. Smith, S. Gamerman, S. Glazer, J.P. Scott, Prolonged recombinant activated factor VII (rFVIIa). Treatment for severe bleeding and surgical hemostasis in a factor-IX deficient patient with an inhibitor. Paper presented at a meeting of the Society for Pediatric Research, MA (1990).
A. Gringeri, E. Santagostino, P.M. Mannucci, Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody, Haemostasis. 21: 1 (1991).
. L. Tengborn, L. Stigendahl, P.O. Elfstrand, B. Kjellman, S. Glazer, Hemostatically effective treatment with recombinant factor Vila (rFVIIa) of a hemophiliac boy with newly developed inhibitors to factor VIII. Abstract presented at the XIX International Congress of the World Federation of Hemophilia, Washington, D.C., August 14 to 19 (1990).
M.L. Schmidt, H.E. Smith, S. Gamerman, D. DiMichele, S. Glazer, J.P. Scott, Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX deficient patient with an inhibitor, Br J Haematol. 78:460 (1991.)
U. Hedner, M. Feldstedt, S. Glazer, Recombinant FV1Ia in hemophilia treatment, in: Hemophilia and von Willebrands Disease in the 1990s, J.M. Lusher, CM. Kessler, eds., Elsevier Science Publishers B.V. (1991).
J. Ingerslev, M. Feldstedt, S. Sindet-Petersen, Control of hemostasis by recombinant factor Vila in a hemophilia A patient with inhibitors during major oral surgery. Abstract presented at the XIX International Congress of the World Federation of Hemophilia, Washington, D.C, August 14 to 19 (1990).
S.F. Stein, A. Duncan, D. Cutler, S. Glazer, Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor Vila. Abstract presented at the American Society of Hematology 32nd Annual Meeting, Boston, MA, November 28 to December 4 (1990).
U. Hedner, Factor Vila in the treatment of haemophilia, Blood Coagul Fibrinolysis. 1: 307 (1990).
B.A. Bell, K. Birch, S. Glazer, Experience with recombinant factor Vila in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report. Am J Pediatr Hematol Oncol. 15: 77 (1993).
S. Schulman, A therapeutic alternative for haemophiliacs with inhibitors. Acta Pediatr. 81, paper 926 (1992).
J. Ingerslev, L. Knudsen, S. Sindet-Petersen, Haemostatic efficacy of recombinant factor Vila in haemophilia A patients with inhibitors. Abstract presented at the XX International Congress of the World Federation of Hemophilia, Athens, Greece, October 12 to 17(1992).
J. Ingerslev, L. Knudsen, S. Sindet-Petersen, Clinical experiences with recombinant factor Vila in haemophilia A patients with inhibitors. Abstract presented at the 3rd Bari International Conference on Factor VIII/von Willebrand Factor, Foggia, Italy, June 7 to 13 (1992).
M. Makris, Recombinant factor Vila: The UK experience. Abstract presented at the 24th Congress of the International Society of Hematology, London, UK, August 23 to 27 (1992).
U. Hedner, S. Glazer, Management of hemophilia patients with inhibitors, Hematol Oncol Clin North Am6: 1035 (1992).
M.L. Schmidt, S. Gamerman, H.E. Smith, J.P. Scott, D. DiMichelle, Recombinant activated factor VII (rFVIIa) therapy for muscle and soft tissue hemorrhage in factor VIII and IX-defìcient patients with inhibitors. Abstract presented at the 33rd Annual Meeting and Exposition of the American Society of Hematology, Denver, Colorado, December 6 to 10 (1991).
MX. Schmidt, S. Gamerman, H.E. Smith, J.P. Scott, D. DiMichelle, Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage (ICH) in hemophilia A patients with inhibitors. Abstract presented at the 33rd Annual Meeting and Exposition of the American Society of Hematology, Denver, Colorado, December 6 to 10 (1991).
D.B. Brettler, A.D. Forsberg, RH. Levine, et al, The use of porcine factor VIII concentrate (HyateiC) in the treatment of patients with inhibitor antibodies to factor FVIII, Arch Intern Med. 149: 1381 (1989).
J.M. Lusher, et al., Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII, N Eng J Med. 303: 421 (1980).
L.J.M. Sjamsoedin, et al., The effect of activated prothrombin-complex concentrate (Feiba) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor Vili. A double-blind clinical trial, N Engl J Med305: 717 (1981).
J.M. Lusher, PM. Blatt, J.A. Penner, et al., Autoplex versus proplex: A controlied, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII, Blood62: 1135 (1983).
M. Hilgartner, L. Aledort, A. Andes, J.C. Gill, Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients, Transfusion30: 626 (1990)
CK. Kasper, L. Boylen, N. Ewing, J.V. Luck, S.L. Dietrich, Hematologic management of hemophilia A for surgery, JAMA. 253: 1279 (1985).
L. Johansen, D. Bucher, L.L. Hansen, H. Kastberg, CM. Lindley, P. Madsen, W.T. Sawyer, Relation between factor Vila coagulant activity and PT and between factor Vila coagulant activity and APTT in human plasma, Abstract presented at the XlVth Congress of the International Society on Thrombosis and Hemostasis, New York, USA, July 4 - 9 (1993).
D.S.C Telgt, B.G. Macik, D.M. McCord, D.M. Monroe, H.R. Roberts, Mechanism by which recombinant factor Vila shortens the aPTT: Activation of factor X in the absence of tissue factor, Thromb Res. 56:603(1989).
I.M. Nilsson, U. Hedner, A. Ahlberg, et al.. Surgery of hemophiliacs-20 years’ experience, World J Surg. 1:55(1977).
R.P.C. Rodgers, J. Levin, A critical reappraisal of the bleeding time, Semin Thromb Hemost. 16 No.1(1990).
H.J. Weiss, B. Lages, Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds, Blood629: 635 (1988).
U. Hedner, D. Bergqvist, J. Ljungberg, B. Nilsson, Haemostatic effect of factor Vila in thrombocytopenic rabbits, Blood. 66:1043(1985).
J. Kristensen, A. Killander, E. Hippe, C. Helleberg, J. Ellegaard, M. Holm, U. Hedner, Recombinant factor Vila (rFVIIa) reduces the bleeding time in patients with thrombocytopenia, Abstract submitted to The American Society of Hematology 35th Annual Meeting, St. Louis, USA, December 3–7 (1993).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
Glazer, S., Hedner, U., Falch, J.F. (1995). Clinical update on the use of recombinant factor VII. In: Aledort, L.M., Hoyer, L.W., Lusher, J.M., Reisner, H.M., White, G.C. (eds) Inhibitors to Coagulation Factors. Advances in Experimental Medicine and Biology, vol 386. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0331-2_15
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0331-2_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8001-6
Online ISBN: 978-1-4613-0331-2
eBook Packages: Springer Book Archive